Clinical Trial Update: Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating AK112 (Yiwoxidan Anti) as monotherapy for metastatic clear cell renal cell carcinoma in patients intolerant to TKIs. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• AK112 (Yiwoxidan Anti) (AK112)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Status: ENROLLING_BY_INVITATION